Publication originale de Paul-Louis Belletante, Président de Boli Care.
Are we a “GLP-1 startup”? The answer might... surprise you.
One of the most (first) common reactions our team hears from physicians is:
“So basically, you’re a GLP-1 startup, right?”
We understand the perception.
But the reality is quite different.
Boli Care does not define itself as a GLP-1 company.
(And no offense at all to companies that do. Many of them are doing important work for patients.)
GLP-1 therapies are transforming obesity care and helping millions of people. But Boli Care’s vision is broader than a drug class.
What truly matters to us is cardiometabolic health: the complex biological systems involved in energy regulation, metabolism, weight regulation, inflammation, and long-term health.
Obesity is one of the clearest clinical manifestations of cardiometabolic dysfunction.
And it is where Boli Care chose to start.
(And for those who follow us closely… yes, that is partly where our name comes from. 😮 )
The arrival of GLP-1 therapies changes everything because, for the first time, we have treatments capable of producing major clinical outcomes at scale.
But there is still a major challenge.
These therapies perform extremely well in clinical trials, and often far less well in real life.
Why?
Because in real life, patients are often alone between consultations.
Alone to manage side effects.
Alone to adapt their nutrition and habits.
Alone to understand why they are, or are not, losing weight.
And often alone against the psychological burden of obesity itself.
Without support between consultations, even the best therapies struggle to reach their full potential.
This is where Boli Care positions itself.
Not as a GLP-1 startup, but as a digital medical device designed to support patients between consultations.
The platform helps patients better navigate treatment while helping physicians better understand what happened between visits.
Because when patient-reported data is continuously structured, consultations become more human, more precise, and more focused on outcomes.
And Boli Care wants to go even further.
The platform is built around a digital phenotyping engine designed to better understand cardiometabolic health through longitudinal real-world data.
Yes, there is much more to come !!
So no, Boli Care is not a GLP-1 startup.
Boli Care is building a new layer of support and intelligence around cardiometabolic care.
Just startin' !
#DTx #obesity #cardiometaboliccare #bolicare #AgenticAI #digitalhealth